Artelo Biosciences (ARTL) Stock Price, News & Analysis

Company Overview

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Key Stats

• Today's Range: $5.77 to $6.15
• 50-Day Range: $5.43 to $7.20
• 52-Week Range: $4.92 to $9.30
• Volume: 9,045 shs
• Average Volume: 23,368 shs
• Market Capitalization: $3.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.00
• Consensus Rating: Buy

Artelo Biosciences Stock Analysis - MarketRank™

Artelo Biosciences scored higher than 48% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Artelo Biosciences has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Artelo Biosciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Artelo Biosciences are expected to grow in the coming year, from ($2.62) to ($1.61) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Artelo Biosciences is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Artelo Biosciences is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Artelo Biosciences has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.93% of the float of Artelo Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Artelo Biosciences has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Artelo Biosciences has recently decreased by 43.90%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Artelo Biosciences does not currently pay a dividend.

Dividend Growth

Artelo Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.93% of the float of Artelo Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Artelo Biosciences has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Artelo Biosciences has recently decreased by 43.90%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Artelo Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.83% of the stock of Artelo Biosciences is held by insiders.

Percentage Held by Institutions

Only 0.87% of the stock of Artelo Biosciences is held by institutions.

ARTL Stock Analysis - Frequently Asked Questions

How have ARTL shares performed this year?

Artelo Biosciences' stock was trading at $6.36 at the start of the year. Since then, ARTL shares have decreased by 7.5% and is now trading at $5.88.
View the best growth stocks for 2025 here.

How were Artelo Biosciences' earnings last quarter?

Artelo Biosciences, Inc. (NASDAQ:ARTL) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($4.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.78) by $3.54.

When did Artelo Biosciences' stock split?

Artelo Biosciences's stock reverse split on Friday, June 13th 2025.The 1-6 reverse split was announced on Wednesday, June 11th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 12th 2025. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

How do I buy shares of Artelo Biosciences?

Shares of ARTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Artelo Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Artelo Biosciences investors own include Meta Platforms (META), NVIDIA (NVDA), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 6/24/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ARTL
• CIK: 1621221
• Web: www.artelobio.com
• Phone: (858) 925-7049
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $33.00
• High Stock Price Target: $36.00
• Low Stock Price Target: $30.00
• Potential Upside/Downside: +461.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($17.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.83 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -226.99%
• Return on Assets: -164.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.49
• Quick Ratio: 0.49

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.31 per share
• Price / Book: 1.11

Miscellaneous

• Outstanding Shares: 550,000
• Free Float: 542,000
• Market Cap: $3.23 million
• Optionable: Not Optionable
• Beta: 1.03